Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial

Chih Jian Lih, David J. Sims, Robin D. Harrington, Eric Polley, Yingdong Zhao, Michele G. Mehaffey, Thomas D. Forbes, Biswajit Das, William D. Walsh, Vivekananda Datta, Kneshay N. Harper, Courtney H. Bouk, Lawrence V. Rubinstein, Richard M. Simon, Barbara A. Conley, Alice P. Chen, Shivaani Kummar, James H. Doroshow, Paul M. Williams

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Robust and analytically validated assays are essential for clinical studies. We outline an analytical validation study of a targeted next-generation sequencing mutation-detection assay used for patient selection in the National Cancer Institute Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT) trial (NCT01827384). Using DNA samples from normal or tumor cell lines and xenografts with known variants, we assessed the sensitivity, specificity, and reproducibility of the NCI-MPACT assay in five variant types: single-nucleotide variants (SNVs), SNVs at homopolymeric (HP) regions (≥3 identical bases), small insertions/deletions (indels), large indels (gap ≥4 bp), and indels at HP regions. The assay achieved sensitivities of 100% for 64 SNVs, nine SNVs at HP regions, and 11 large indels, 83.33% for six indels, and 93.33% for 15 indels at HP regions. Zero false positives (100% specificity) were found in 380 actionable mutation loci in 96 runs of haplotype map cells. Reproducibility analysis showed 96.3% to 100% intraoperator and 98.1% to 100% interoperator mean concordance in detected variants and 100% reproducibility in treatment selection. To date, 38 tumors have been screened, 34 passed preanalytical quality control, and 18 had actionable mutations for treatment assignment. The NCI-MPACT assay is well suited for its intended investigational use and can serve as a template for developing next-generation sequencing assays for other cancer clinical trial applications.

Original languageEnglish (US)
Pages (from-to)51-67
Number of pages17
JournalJournal of Molecular Diagnostics
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

National Cancer Institute (U.S.)
Nucleotides
Mutation
Neoplasms
Therapeutics
Validation Studies
Tumor Cell Line
Heterografts
Quality Control
Haplotypes
Patient Selection
Clinical Trials
Sensitivity and Specificity
DNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. / Lih, Chih Jian; Sims, David J.; Harrington, Robin D.; Polley, Eric; Zhao, Yingdong; Mehaffey, Michele G.; Forbes, Thomas D.; Das, Biswajit; Walsh, William D.; Datta, Vivekananda; Harper, Kneshay N.; Bouk, Courtney H.; Rubinstein, Lawrence V.; Simon, Richard M.; Conley, Barbara A.; Chen, Alice P.; Kummar, Shivaani; Doroshow, James H.; Williams, Paul M.

In: Journal of Molecular Diagnostics, Vol. 18, No. 1, 01.01.2016, p. 51-67.

Research output: Contribution to journalArticle

Lih, CJ, Sims, DJ, Harrington, RD, Polley, E, Zhao, Y, Mehaffey, MG, Forbes, TD, Das, B, Walsh, WD, Datta, V, Harper, KN, Bouk, CH, Rubinstein, LV, Simon, RM, Conley, BA, Chen, AP, Kummar, S, Doroshow, JH & Williams, PM 2016, 'Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial', Journal of Molecular Diagnostics, vol. 18, no. 1, pp. 51-67. https://doi.org/10.1016/j.jmoldx.2015.07.006
Lih, Chih Jian ; Sims, David J. ; Harrington, Robin D. ; Polley, Eric ; Zhao, Yingdong ; Mehaffey, Michele G. ; Forbes, Thomas D. ; Das, Biswajit ; Walsh, William D. ; Datta, Vivekananda ; Harper, Kneshay N. ; Bouk, Courtney H. ; Rubinstein, Lawrence V. ; Simon, Richard M. ; Conley, Barbara A. ; Chen, Alice P. ; Kummar, Shivaani ; Doroshow, James H. ; Williams, Paul M. / Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. In: Journal of Molecular Diagnostics. 2016 ; Vol. 18, No. 1. pp. 51-67.
@article{1ec4437f1f0241a7a11199383c0053a8,
title = "Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial",
abstract = "Robust and analytically validated assays are essential for clinical studies. We outline an analytical validation study of a targeted next-generation sequencing mutation-detection assay used for patient selection in the National Cancer Institute Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT) trial (NCT01827384). Using DNA samples from normal or tumor cell lines and xenografts with known variants, we assessed the sensitivity, specificity, and reproducibility of the NCI-MPACT assay in five variant types: single-nucleotide variants (SNVs), SNVs at homopolymeric (HP) regions (≥3 identical bases), small insertions/deletions (indels), large indels (gap ≥4 bp), and indels at HP regions. The assay achieved sensitivities of 100{\%} for 64 SNVs, nine SNVs at HP regions, and 11 large indels, 83.33{\%} for six indels, and 93.33{\%} for 15 indels at HP regions. Zero false positives (100{\%} specificity) were found in 380 actionable mutation loci in 96 runs of haplotype map cells. Reproducibility analysis showed 96.3{\%} to 100{\%} intraoperator and 98.1{\%} to 100{\%} interoperator mean concordance in detected variants and 100{\%} reproducibility in treatment selection. To date, 38 tumors have been screened, 34 passed preanalytical quality control, and 18 had actionable mutations for treatment assignment. The NCI-MPACT assay is well suited for its intended investigational use and can serve as a template for developing next-generation sequencing assays for other cancer clinical trial applications.",
author = "Lih, {Chih Jian} and Sims, {David J.} and Harrington, {Robin D.} and Eric Polley and Yingdong Zhao and Mehaffey, {Michele G.} and Forbes, {Thomas D.} and Biswajit Das and Walsh, {William D.} and Vivekananda Datta and Harper, {Kneshay N.} and Bouk, {Courtney H.} and Rubinstein, {Lawrence V.} and Simon, {Richard M.} and Conley, {Barbara A.} and Chen, {Alice P.} and Shivaani Kummar and Doroshow, {James H.} and Williams, {Paul M.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.jmoldx.2015.07.006",
language = "English (US)",
volume = "18",
pages = "51--67",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "1",

}

TY - JOUR

T1 - Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial

AU - Lih, Chih Jian

AU - Sims, David J.

AU - Harrington, Robin D.

AU - Polley, Eric

AU - Zhao, Yingdong

AU - Mehaffey, Michele G.

AU - Forbes, Thomas D.

AU - Das, Biswajit

AU - Walsh, William D.

AU - Datta, Vivekananda

AU - Harper, Kneshay N.

AU - Bouk, Courtney H.

AU - Rubinstein, Lawrence V.

AU - Simon, Richard M.

AU - Conley, Barbara A.

AU - Chen, Alice P.

AU - Kummar, Shivaani

AU - Doroshow, James H.

AU - Williams, Paul M.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Robust and analytically validated assays are essential for clinical studies. We outline an analytical validation study of a targeted next-generation sequencing mutation-detection assay used for patient selection in the National Cancer Institute Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT) trial (NCT01827384). Using DNA samples from normal or tumor cell lines and xenografts with known variants, we assessed the sensitivity, specificity, and reproducibility of the NCI-MPACT assay in five variant types: single-nucleotide variants (SNVs), SNVs at homopolymeric (HP) regions (≥3 identical bases), small insertions/deletions (indels), large indels (gap ≥4 bp), and indels at HP regions. The assay achieved sensitivities of 100% for 64 SNVs, nine SNVs at HP regions, and 11 large indels, 83.33% for six indels, and 93.33% for 15 indels at HP regions. Zero false positives (100% specificity) were found in 380 actionable mutation loci in 96 runs of haplotype map cells. Reproducibility analysis showed 96.3% to 100% intraoperator and 98.1% to 100% interoperator mean concordance in detected variants and 100% reproducibility in treatment selection. To date, 38 tumors have been screened, 34 passed preanalytical quality control, and 18 had actionable mutations for treatment assignment. The NCI-MPACT assay is well suited for its intended investigational use and can serve as a template for developing next-generation sequencing assays for other cancer clinical trial applications.

AB - Robust and analytically validated assays are essential for clinical studies. We outline an analytical validation study of a targeted next-generation sequencing mutation-detection assay used for patient selection in the National Cancer Institute Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT) trial (NCT01827384). Using DNA samples from normal or tumor cell lines and xenografts with known variants, we assessed the sensitivity, specificity, and reproducibility of the NCI-MPACT assay in five variant types: single-nucleotide variants (SNVs), SNVs at homopolymeric (HP) regions (≥3 identical bases), small insertions/deletions (indels), large indels (gap ≥4 bp), and indels at HP regions. The assay achieved sensitivities of 100% for 64 SNVs, nine SNVs at HP regions, and 11 large indels, 83.33% for six indels, and 93.33% for 15 indels at HP regions. Zero false positives (100% specificity) were found in 380 actionable mutation loci in 96 runs of haplotype map cells. Reproducibility analysis showed 96.3% to 100% intraoperator and 98.1% to 100% interoperator mean concordance in detected variants and 100% reproducibility in treatment selection. To date, 38 tumors have been screened, 34 passed preanalytical quality control, and 18 had actionable mutations for treatment assignment. The NCI-MPACT assay is well suited for its intended investigational use and can serve as a template for developing next-generation sequencing assays for other cancer clinical trial applications.

UR - http://www.scopus.com/inward/record.url?scp=84954055993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954055993&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2015.07.006

DO - 10.1016/j.jmoldx.2015.07.006

M3 - Article

C2 - 26602013

AN - SCOPUS:84954055993

VL - 18

SP - 51

EP - 67

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 1

ER -